Elevidys Availability in 2026: What's Changed

If you're a parent or caregiver of a child with Duchenne muscular dystrophy (DMD), keeping up with Elevidys (Delandistrogene Moxeparvovec-rokl) availability has been an emotional rollercoaster. From its initial FDA approval in 2023 to the safety concerns and shipment pauses of 2025, the landscape has shifted dramatically.

Here's what you need to know about Elevidys availability as of early 2026.

Is Elevidys Still in Shortage?

The situation with Elevidys is complex. It's not a traditional "drug shortage" in the way you might experience with a common prescription medication. Instead, the availability challenges stem from:

• Regulatory restrictions — The FDA narrowed the approved indication to ambulatory patients only
• The 2025 shipment pause — All shipments were temporarily halted
• Limited treatment infrastructure — Only specialized centers can administer gene therapy
• Complex insurance requirements — Extensive prior authorization for a $3.2 million treatment

For ambulatory patients who meet the current eligibility criteria, Elevidys shipments have resumed. However, access remains challenging due to the factors above. For non-ambulatory patients, Elevidys is no longer available following the FDA's indication restriction.

Why Has Elevidys Been Hard to Find?

The Safety Events of 2025

In 2025, reports emerged of fatal acute liver failure in non-ambulatory DMD patients treated with Elevidys. This triggered a series of critical events:

1. June 2025: Sarepta voluntarily halted shipments for non-ambulatory patients to allow an expert committee to evaluate additional safety measures
2. July 21, 2025: Sarepta extended the pause to all Elevidys shipments following an informal FDA request
3. Late 2025: The FDA approved major labeling changes including a new Boxed Warning for serious liver injury and acute liver failure (including fatal outcomes)
4. Late 2025: The indication was restricted to ambulatory patients only, and shipments resumed for this population

These events significantly disrupted the treatment pipeline for families who were in various stages of the access process.

Insurance and Cost Barriers

At $3.2 million per treatment, Elevidys is one of the most expensive therapies in the world. Insurance companies require extensive documentation before approving coverage, including:

• Genetic confirmation of DMD diagnosis
• Documentation of ambulatory status
• Specialist prescription from a qualified neuromuscular physician
• Evidence that the patient meets all eligibility criteria

Initial denials are common, and the appeals process can add weeks or months to the timeline.

What Does Elevidys Cost in 2026?

The wholesale acquisition cost (WAC) of Elevidys remains approximately $3.2 million for the one-time treatment. This applies regardless of which weight-based kit is used — the 21.5-22.4 kg kit or any other size.

Because this is a one-time gene therapy (not an ongoing medication), the cost structure is different from traditional drugs. Most of the financial burden falls on insurance rather than patient out-of-pocket costs, but navigating coverage requires significant effort.

Sarepta's SareptAssist program can help eligible families with financial assistance. Learn more in our article on saving money on Elevidys.

Are There New Options for DMD Patients?

The DMD treatment landscape continues to evolve:

• Updated Elevidys protocol — The revised prescribing information includes updated corticosteroid regimens and monitoring requirements designed to improve safety
• Exon-skipping therapies — Eteplirsen (Exondys 51), Casimersen (Amondys 45), and Viltolarsen (Viltepso) remain available for patients with amenable mutations
• Corticosteroids — Deflazacort (Emflaza) continues as first-line treatment for most DMD patients
• Clinical trials — Several next-generation gene therapies and other novel approaches are in development

For a detailed comparison of alternatives, read our guide to Elevidys alternatives.

How to Find Elevidys in Stock

If your child is an eligible ambulatory patient, here's how to pursue Elevidys access:

Step 1: Confirm Eligibility

Work with your child's neurologist to confirm they meet all current criteria:

• Ambulatory (able to walk)
• Age 4 or older
• Confirmed DMD gene mutation amenable to treatment
• No deletion affecting exons 8 or 9
• No preexisting liver impairment
• No recent vaccinations or active infections

Step 2: Contact SareptAssist

Call 1-888-727-3782 to connect with SareptAssist. They can help identify treatment centers, navigate insurance, and coordinate logistics.

Step 3: Use Medfinder

Use Medfinder to stay informed about treatment center availability and medication access. Read our detailed guide on finding Elevidys for more tips.

Step 4: Start Insurance Authorization Early

Don't wait. Begin the prior authorization process as soon as your neurologist determines your child is a candidate. The process can take weeks to months, and starting early gives you time for appeals if needed.

Final Thoughts

The Elevidys story in 2025-2026 has been marked by both hope and heartbreak. The safety events that led to the shipment pause and label changes were devastating for the DMD community, particularly families of non-ambulatory patients who lost access to the therapy.

For eligible ambulatory patients, Elevidys remains available but challenging to access. The combination of limited treatment centers, complex insurance requirements, and the aftermath of the 2025 safety concerns means that families need patience, persistence, and the right support network.

Stay informed, work closely with your medical team, and take advantage of every resource available — from SareptAssist to patient advocacy groups like PPMD and MDA. For more information, visit our articles on understanding Elevidys, side effects to watch for, and checking treatment center availability.